A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs HLA DQ2 peptide vaccine (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions
  • Sponsors ImmusanT
  • Most Recent Events

    • 22 Feb 2017 Results of this trial supports a dosing regimen for a Phase II trial (see profile 258610), according to a ImmusanT media release.
    • 22 Feb 2017 Status changed from active, no longer recruiting to completed, as reported in an ImmusanT media release.
    • 07 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top